On the heels of a potential $1 billion oncology collaboration, Incyte Corp.'s JAK program snagged another partner, licensing oral JAK/JAK2 inhibitor INCB28050 to Eli Lilly and Co. in a potential $755 million deal that gives the biotech some big pharma muscle in the crowded rheumatoid arthritis space. (BioWorld Today)